Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies | MicrobiomeTrials
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-09-15Est. Completion: 2029-09-27
Enrollment target: 63 participants
Locations
UC Irvine, Orange, California, United States
CBCI, Colorado Blood Cancer Institute, Denver, Colorado, United States
SSAK Partners, Coral Springs, Florida, United States
Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
Indiana University Health Arnett, Inc., Lafayette, Indiana, United States
Johns Hopkins Asthma & Allergy Center, Baltimore, Maryland, United States
American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
Hackensack Meridian Health, Hackensack, New Jersey, United States
Carol G Simon Cancer Center, Morristown, New Jersey, United States
David H. Koch Center for Cancer Care, New York, New York, United States
Montefiore Medical Center PRIME, The Bronx, New York, United States
Duke University, Durham, North Carolina, United States
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Penn State Hershey Medical Center, Hershey, Pennsylvania, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Other microbiome trials you might be interested in